2H-1,2,3-benzothiadiazine-1,1-dione - CAS 21639-39-4
Catalog: |
BB055043 |
Product Name: |
2H-1,2,3-benzothiadiazine-1,1-dione |
CAS: |
21639-39-4 |
Synonyms: |
2H-1,2,3-Benzothiadiazine 1,1-dioxide; 2H-1,2,3-Benzothiadiazine-1,1-dione; 2H-1lambda6,2,3-benzothiadiazine 1,1-dioxide; 2H-1??,2,3-benzothiadiazine-1,1-dione; benzothiadiazine s,s-dioxide |
IUPAC Name: | 2H-1λ6,2,3-benzothiadiazine 1,1-dioxide |
Molecular Weight: | 182.19 |
Molecular Formula: | C7H6N2O2S |
Canonical SMILES: | C1=CC=C2C(=C1)C=NNS2(=O)=O |
InChI: | InChI=1S/C7H6N2O2S/c10-12(11)7-4-2-1-3-6(7)5-8-9-12/h1-5,9H |
InChI Key: | UOCUSOBVEHOMMB-UHFFFAOYSA-N |
GHS Hazard Statement: | H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral] |
Precautionary Statement: | P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 |
Signal Word: | Warning |
Publication Number | Title | Priority Date |
CN-113441184-A | Catalyst for carbodiimide amination synthesis, synthesis method and obtained guanidyl compound | 20210727 |
CN-113441184-B | Catalyst for carbodiimide amination synthesis, synthesis method and obtained guanidyl compound | 20210727 |
CN-113121470-A | Preparation method of benzothiadiazine-1, 1-dioxide compound | 20210305 |
CN-114163430-A | Benzothiadiazine derivative and application thereof in agriculture | 20200911 |
CN-110818653-A | Benzothiadiazine compound and application thereof, and positron medicine of AMPAR | 20191108 |
CN-110818653-B | Benzothiadiazine compound and application thereof, and positron medicine of AMPAR | 20191108 |
CA-3073794-A1 | Fused [1,2,4]thiadiazine derivatives which act as kat inhibitors of the myst family | 20170831 |
WO-2019043139-A1 | FUSED [1,2,4] THIADIAZINE DERIVATIVES AS KAT INHIBITORS OF THE MYST FAMILY | 20170831 |
EP-3676266-A1 | Fused [1,2,4]thiadiazine derivatives which act as kat inhibitors of the myst family | 20170831 |
JP-2020531593-A | Condensation [1,2,4] thiadiazine derivatives that act as KAT inhibitors of the MYST family | 20170831 |
PMID | Publication Date | Title | Journal |
21629446 | 20101201 | Glutamatergic targets for enhancing extinction learning in drug addiction | Current neuropharmacology |
Complexity: | 291 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 182.01499861 |
Formal Charge: | 0 |
Heavy Atom Count: | 12 |
Hydrogen Bond Acceptor Count: | 4 |
Hydrogen Bond Donor Count: | 1 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 182.01499861 |
Rotatable Bond Count: | 0 |
Topological Polar Surface Area: | 66.9Ų |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 0.4 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Other Building Blocks
Customers Also Viewed
-
[132182-92-4]
Pentane, 1,1,1,2,2,3,4,5,5,5-decafluoro-3-methoxy-4-(trifluoromethyl)-
-
[94086-78-9]
Isopropyl 4-[4-[N,N-bis(2-hydroxyethyl)amino]phenyl]butyrate
-
[1427004-19-0]
DBCO-PEG4-NHS ester
-
[3821-81-6]
3-Amino-2-fluoropropionic acid
-
[471915-89-6]
N-(3,4-Dihydroxyphenethyl)methacrylamide
-
[87117-22-4]
1,4-Bis(2-ethylhexyl)benzene
INDUSTRY LEADERS TRUST OUR PRODUCTS